 While EFTR stock has escaped the usual underperformance of SPAC IPOs so far, eFFECTOR Therapeutics still remains a risky proposition. The post Hold Off on eFFECTOR Therapeutics if You Cant Stomach the Risk appeared first on InvestorPlace. 